Search Results
Mar 19, 2026, 07:30 ET Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
trial participants and has been well tolerated with low rates of serious adverse events (SAEs) and adverse events (AEs) leading to early discontinuation. Rates of muscle- and GI-related AEs have been generally comparable to placebo. In nonclinical studies, taldefgrobep has demonstrated the ability
More news about: Biohaven Ltd.
Mar 19, 2026, 06:23 ET Belief BioMed announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved in Macao, China
Stage Assay actin FSL aPTT reagent). [9] In addition, BBM-H901 exhibited good safety in clinical trials, with no grade 3-4 adverse events (AEs), serious adverse events (SAEs), or inhibitors observed. [9] The studies are still in the process of continuous follow-up.Due to BBM-H901's
More news about: Belief BioMed
Mar 19, 2026, 03:00 ET Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions
Patients taking medications that can prolong bleeding may experience increased bruising or bleeding at treatment sites. Patients may experience late onset AEs with use of injectable gel implants, including SKINVIVE by JUVÉDERM®ADVERSE EVENTS: The most commonly reported injection site
More news about: AbbVie
Mar 18, 2026, 20:00 ET DeskIn Positions Itself as the Execution Layer AI Remote Control Can't Replace
developer running a full build on a home machine while travelling, gets a comparable experience as sitting at the workstation.Security: AES-256 encryption, ISO 27001 and ISO 9001 certification, and precise access controls, designed for compliance-sensitive organisations and individuals. Security
More news about: Zuler Technology
Mar 18, 2026, 17:00 ET Widest Caesium Drill Intercept to Date at the Helios Caesium Zone in Final Batch of 2025 Drill Results from Shaakichiuwaanaan
BC, where the samples were homogenized and subsequently analyzed for multi-element (including Li, Ta, and Cs) using sodium peroxide fusion with ICP-AES/MS finish (codes GE_ICP91A50 and GE_IMS91A50). Overlimits for Cs were completed at SGS Canada's laboratory in Lakefield, ON, by borate-fusion XRF (code
More news about: PMET Resources Inc.
Mar 18, 2026, 08:00 ET MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control
pharmacokinetics (PK), and pharmacodynamics (PD) of DA-1726. Primary endpoints include monitoring adverse events (AEs), serious adverse events (SAEs), treatment-emergent adverse events (TEAEs), and AEs leading to treatment discontinuation. Secondary and exploratory endpoints include PK profiling and evaluation
More news about: MetaVia Inc.
Mar 16, 2026, 20:00 ET DeskIn Extends Reliable Remote Desktop Software to Users Across the Middle East Amid Rising Connectivity Demands
access without needing an enterprise IT budget.Data transmissions are prioritised and secured with technical and access control layers: AES-256 encryption, flexible access controls, clear consent prompts, and ISO 27001 and ISO 9001 certification, ensuring sensitive work and personal data
More news about: Zuler Technology
Mar 16, 2026, 08:30 ET AES Announces Amendments to and Further Extension of Consent Solicitations
ARLINGTON, Va., March 16, 2026 /PRNewswire/ -- The AES Corporation ("AES") (NYSE: AES) today announced that it is amending and extending each of its previously announced solicitations of consents (each, a "Consent Solicitation"
More news about: The AES Corporation
Mar 16, 2026, 08:30 ET DPL LLC Announces Amendments to and Further Extension of Consent Solicitation
respect of the proposed transaction between The AES Corporation ("AES") and Horizon Parent, L.P. ("Parent"). In connection with the proposed transaction, AES expects to file a proxy statement on Schedule 14A with the Securities and Exchange Commission ("SEC"). AES also may file other documents with the SEC
More news about: DPL LLC
Mar 16, 2026, 08:30 ET IPALCO Enterprises, Inc. Announces Amendments to and Further Extension of Consent Solicitations
Enterprises, Inc. is owned by The AES Corporation, a global power company, with CDP Infrastructures Fund L.P., a wholly owned subsidiary of La Caisse de dépôt et placement du Québec (CDPQ), as minority interest holder.About AESThe AES Corporation (NYSE: AES) is a Fortune 500 global energy
More news about: IPALCO Enterprises
Mar 12, 2026, 21:00 ET 실리콘모션, 업계 최초로 엔터프라이즈급 부트 드라이브와 초저전력 스토리지를 위한 전용 PCI Gen5 컨트롤러 SM8008을 출시
다음과 같이 종합적인 엔터프라이즈급 보안 프레임워크를 통합하였다.TCG Opal 2.0 준수 암호화하드웨어 가속 AES-256, SHA2-512, RSA-3072b보안 부팅과 펌웨어 인증DICE와 SPDM 지원2027년부터 국가안보시스템(NSS)에 새로 납품되는 모든 장비들이 CNSA 2.0 표준을 준수해야 한다는 새로운 요구조건에 따라 CNSA
More news about: Silicon Motion Technology Corporation
Mar 12, 2026, 09:00 ET Silicon Motion Launches SM8008, the Industry's First Purpose-Built PCIe Gen5 Controller for Enterprise Boot Drive and Ultra-Low-Power Storage
including:TCG Opal 2.0 compliant encryptionHardware-accelerated AES-256, SHA2-512, and RSA-3072bSecure Boot and firmware authenticationSupport for DICE and SPDMCNSA 2.0 readiness, aligning with
More news about: Silicon Motion Technology Corporation
Mar 12, 2026, 08:30 ET AES Announces Extension of Expiration Time for Previously Announced Consent Solicitations
requiring AES to pay a termination fee or other expenses; (xii) competitive responses to the Transaction; and (xiii) the risks and uncertainties pertaining to AES' business, including those set forth in Part I, Item 1A of AES' most recent Annual Report on Form 10-K and Part II, Item 1A of AES' subsequent
More news about: The AES Corporation
Mar 12, 2026, 08:30 ET IPALCO Enterprises, Inc. Announces Extension of Expiration Time for Previously Announced Consent Solicitations
Enterprises, Inc. is owned by The AES Corporation, a global power company, with CDP Infrastructures Fund L.P., a wholly owned subsidiary of La Caisse de dépôt et placement du Québec (CDPQ), as minority interest holder.About AESThe AES Corporation (NYSE: AES) is a Fortune 500 global energy
More news about: IPALCO Enterprises
Mar 12, 2026, 08:30 ET DPL LLC Announces Extension of Expiration Time for Previously Announced Consent Solicitation
respect of the proposed transaction between The AES Corporation ("AES") and Horizon Parent, L.P. ("Parent"). In connection with the proposed transaction, AES expects to file a proxy statement on Schedule 14A with the Securities and Exchange Commission ("SEC"). AES also may file other documents with the SEC
More news about: DPL LLC
Mar 12, 2026, 07:30 ET Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study
been a total of fourteen (14) grade 3 or higher AEs, only one (1) of which is considered a common immune-related side effect of checkpoint immunotherapy.Cohort B: There has been a total of twenty-five (25) SOC-related grade 3 AEs, of which four (4) are considered common or rare
More news about: Intensity Therapeutics Inc.
Mar 12, 2026, 07:00 ET AES Deploys AI Safety Platform in U.S. Operations
www.aes.com.AES Website DisclosureAES uses its website, including its quarterly updates, as channels of distribution of Company information. The information AES posts through these channels may be deemed material. Accordingly, investors should monitor our website, in addition to following AES' press
More news about: The AES Corporation
Mar 11, 2026, 11:45 ET REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
(n=7) and LDH (n=8).RGX-202 was well tolerated with no serious adverse events (SAEs) and no AEs of special interest (AESIs) in the Phase I/II study as of the data cut date (n=13). Common drug-related AEs included vomiting, fatigue, and nausea. All are typically anticipated with gene therapy administration.
More news about: REGENXBIO Inc.
Mar 11, 2026, 08:30 ET Quantum Computing Inc. and Ciena Demonstrate Next-Generation Quantum-Secured Communications with High-Speed Encryption using PQC and QKD at OFC 2026
showcases a comprehensive security architecture integrating quantum key distribution, quantum authentication, classical authentication, and high-performance AES-256-GCM optical encryption.The solution is designed to address both current cybersecurity threats and future risks posed by quantum computers
More news about: Quantum Computing Inc.
Mar 10, 2026, 12:30 ET Acer Debuts First TravelMate P4 & P2 Copilot+ PCs Featuring Intel Core Ultra Series 3 Processors with Intel vPro
gamut sRGB 100% with integrated multi-touch, support for AES2.0 stylus14.0" WUXGA 1920 x 1200 resolution LED-backlit IPS LCD with integrated multi-touch, 16:10 aspect ratio, support for AES2.0 stylus, 120Hz refresh rate
More news about: Acer
Mar 10, 2026, 08:31 ET Revenue Optics Launches Talent Infrastructure Platform for SaaS Revenue Hiring and Appoints Sabz Kaur to Lead Growth
New platform helps B2B SaaS companies hire SDRs and AEs faster through AI driven candidate bench building, sales assessment, and governed hiring.MEMPHIS, Tenn., March 10, 2026 /PRNewswire/ -- Revenue Optics today
More news about: Revenue Optics
Mar 10, 2026, 08:00 ET Lipocine Announces Financial Results for the Full Year Ended December 31, 2025
2025 American Epilepsy Society (AES) Annual Meeting that took place in December 2025 in Atlanta, Georgia. Oral Toxicokinetics of a Bioidentical GABAA
More news about: Lipocine Inc.
Mar 10, 2026, 06:00 ET Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity
due to adverse events (AEs) for either ASC30 SQ depot formulations A1 and A2 or placebo-treated participants. All AEs, including injection site AEs, were mild to moderate in severity. All gastrointestinal (GI) AEs were mild (grade 1) with no moderate (grade 2) or above GI AEs. No hepatic safety signal
More news about: Ascletis Pharma Inc.
Mar 07, 2026, 17:51 ET TTW Picks Best 50 Heritage Travel Destinations in the World for 2026
Oslo Airport, Gardermoen (OSL) / Tromsø Airport (TOS)West Norwegian Fjords – Geirangerfjord and Nærøyfjord – Ålesund Airport, Vigra (AES) / Bergen Airport (BGO)Rjukan-Notodden Industrial Heritage Site – Oslo Airport, Gardermoen (OSL) / Sandefjord Airport, Torp (TRF)Kongsberg
More news about: Travel And Tour World
Mar 06, 2026, 11:15 ET Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders?
about your legal rights and options.The AES Corporation (NYSE: AES)'s sale to a consortium led by Global Infrastructure Partners and the EQT Infrastructure VI fund for $15.00 per share in cash. If you are an AES shareholder,
More news about: Halper Sadeh LLP